Position in BIOA
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$2,907,257
New position
Shares Held
166,224
first reported quarter
Ownership
0.374%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Ensign Peak Advisors, Inc holds $59,723,780 across 18 Drug Manufacturers - Specialty & Generic names. BIOA ranks #4 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
181,481 | $23,908,306 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
25,292 | $14,997,650 | |
| 3 | ZTS |
Zoetis Inc.
|
108,357 | $12,808,880 | |
| 4 | BIOA |
BioAge Labs, Inc.
This page
|
166,224 | $2,907,257 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
40,850 | $1,230,402 | |
| 6 | VTRS |
Viatris Inc
|
65,686 | $887,417 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
31,510 | $754,034 | |
| 8 | PBH |
Prestige Consumer Healthcare Inc.
|
5,785 | $342,876 |
All Filings in BIOA
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,907,257 | 166,224 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||